Probiotics in Acute Diarrhea (IAP 2025 Consensus)

Pathophysiology And Rationale

Acute infectious diarrhea precipitates profound gut dysbiosis, compromises tight junctions leading to a leaky gut, and triggers a pro-inflammatory cytokine cascade.
Probiotics actively reverse dysbiosis via competitive exclusion, antimicrobial peptide secretion (lactic acid and bacteriocins), epithelial barrier enhancement (upregulating MUC2 and zonula occludens-1), and immunomodulation (stimulating GALT and sIgA secretion).

The Indian Academy of Pediatrics consensus strictly emphasizes strain specificity and disease specificity, refuting the generalization of probiotic efficacy across different strains.
Single-strain formulations hold the highest quality of evidence for acute infectious diarrhea over multi-strain cocktails.

Lactobacillus rhamnosus GG (LGG): Conditionally recommended as an adjunctive therapy in acute watery diarrhea of suspected viral etiology. The optimal dosage is $10^{10}$ to $10^{11}$ Colony Forming Units per day for 5 to 7 days.
Saccharomyces boulardii (CNCM I-745): This non-pathogenic yeast carries a conditional recommendation for acute watery diarrhea. Being a eukaryotic yeast, it resists antibacterial antibiotics. Standard pediatric dosage is 250 mg once or twice daily.

Despite widespread prescription in India due to room-temperature spore stability, the Indian Academy of Pediatrics notes its clinical evidence is substantially weaker than LGG or S. boulardii.

Acute Dysentery: Probiotics have zero proven efficacy in invasive bacterial diarrhea with visible blood, which mandates targeted systemic antimicrobials.
Persistent Diarrhea: Explicitly not recommended for diarrhea lasting 14 days or more due to complex mucosal injury.
High-Risk Patient Profiles: Severe Acute Malnutrition, immunocompromised states, and intensive care patients with central venous catheters carry a documented, life-threatening risk of probiotic-induced bacteremia or fungemia.

The World Health Organization explicitly issued a conditional recommendation against probiotic use for acute watery diarrhea in children up to 10 years of age.
Rationale centers on marginal clinical benefit (diarrhea duration reduced by only 18 to 24 hours without mortality or hospitalization reduction), high cost diverting resources from life-saving Zinc or Low-Osmolarity ORS, and prevalent cold-chain failures yielding non-viable products in developing nations.

The European Society for Paediatric Gastroenterology Hepatology and Nutrition revised its guidelines to a weak recommendation exclusively for LGG or S. boulardii.
Explicitly recommends against Lactobacillus reuteri and Bacillus clausii for acute gastroenteritis.

Antibiotic-Associated Diarrhea represents a distinct clinical indication resulting from commensal flora eradication by broad-spectrum antibiotics.
Indian Academy of Pediatrics and global societies strongly align in recommending S. boulardii and high-dose LGG for the prevention of Antibiotic-Associated Diarrhea.